Pulmonx Corp. (LUNG) News

Pulmonx Corp. (LUNG): $9.19

0.17 (+1.88%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LUNG News Items

LUNG News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LUNG News Highlights

  • For LUNG, its 30 day story count is now at 2.
  • Over the past 21 days, the trend for LUNG's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest LUNG News From Around the Web

Below are the latest news stories about PULMONX CORP that investors may wish to consider to help them evaluate LUNG as an investment opportunity.

Pulmonx (NASDAQ:LUNG) investors are sitting on a loss of 66% if they invested a year ago

Even the best stock pickers will make plenty of bad investments. Unfortunately, shareholders of Pulmonx Corporation...

Yahoo | January 31, 2023

Was anything positive for Pulmonx Corporation (LUNG) stock last session?

In Monday’s session, Pulmonx Corporation (NASDAQ:LUNG) marked $8.07 per share, up from $7.79 in the previous session. While Pulmonx Corporation has overperformed by 3.59%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LUNG fell by -74.88%, with highs and lows ranging from $32.12 to $4.07, whereas […]

US Post News | January 10, 2023

Steven Cohen’s Point72 Discloses 5.3% Pulmonx Stake As BofA Downgrades The Stock

Discusses the latest hedge fund position with quant analysis and market commentary On Wednesday evening after the closure of US equity markets, a 13G filing with the SEC revealed Steven Cohen’s hedge fund Point72 had disclosed a 5.3% stake in lunch disease focused biopharma company Plumonx (NASDAQ:LUNG). The filing came only one day after BofA’s […]

ValueWalk | January 5, 2023

Point72 Asset Management shows 5.3% stake in Pulmonx (NASDAQ:LUNG)

Pulmonx (LUNG) Form SC 13G filing shows a total 5.3% stake of Point72 Asset Management in the company.Number of shares owned by Point72 Asset Management is ~1.96M.The stock has par…

Seeking Alpha | January 5, 2023

PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday

U.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Tuesday. Here are some big stocks recording losses in today’s session. SoundHound AI, Inc. (NASDAQ: SOUN ) shares dipped 19% to $1.43 after climbing around 72% on Friday. Inter & Co, Inc. (NASDAQ: INTR ) dropped 17.7% to $1.9501. Mammoth Energy Services, Inc. (NASDAQ: TUSK ) fell 17.3% to $7.15. Valens Semiconductor Ltd. (NYSE: VLN ) declined 17% to $4.4800. PDS Biotechnology Corporation (NASDAQ: PDSB ) fell 15.3% to $11.18. PDS Biotech announced exclusive global license agreement for investigational IL-12 tumor-targeted cytokine … Full story available on Benzinga.com

Benzinga | January 3, 2023

LUNG (Pulmonx Corporation) has impressive results

As of Friday, Pulmonx Corporation’s (NASDAQ:LUNG) stock closed at $8.43, up from $8.21 the previous day. While Pulmonx Corporation has overperformed by 2.68%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LUNG fell by -74.39%, with highs and lows ranging from $36.26 to $4.07, whereas the […]

US Post News | January 2, 2023

These Numbers Show Just How Powerful Pulmonx Corporation (NASDAQ: LUNG) Stock ‎Is

Pulmonx Corporation (NASDAQ:LUNG) price closed higher on Tuesday, December 20, jumping 11.05% above its previous close. A look at the daily price movement shows that the last close reads $7.06, with intraday deals fluctuated between $7.07 and $8.18. The company’s 5Y monthly beta was ticking 1.44. Taking into account the 52-week price action we note … These Numbers Show Just How Powerful Pulmonx Corporation (NASDAQ: LUNG) Stock ‎Is Read More »

Stocks Register | December 21, 2022

American Lung Association Campaign Shines Spotlight on Endobronchial Valves for Advanced COPD/Emphysema

REDWOOD CITY, Calif., December 14, 2022--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Association to provide education to patients and providers on Endobronchial Valves, a clinically proven treatment to help people with severe COPD/emphysema breathe easier.1 COPD has no cure and is the third leading cause of death worldwide. Individuals living with advanced disease often struggle with ea

Yahoo | December 14, 2022

Have you been able to find a good deal on Pulmonx Corporation’s shares?

Pulmonx Corporation (NASDAQ:LUNG) marked $6.08 per share on Tuesday, down from a previous closing price of $6.18. While Pulmonx Corporation has underperformed by -1.62%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, LUNG fell by -80.62%, with highs and lows ranging from $36.37 to $4.07, whereas […]

US Post News | December 7, 2022

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema.

Business Wire | November 30, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4693 seconds.